PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects

International Journal of Cancer

Volumn 137, Issue 1, 2015, Pages 243-250

  Tsubaki, Masanobu ^a   Takeda, Tomoya ^a   Tani, Tadahumi ^a   Shimaoka, Hirotaka ^a   Suzuyama, Naohiro ^a   Sakamoto, Kotaro ^a   Fujita, Arisa ^a   Ogawa, Naoki ^a,b   Itoh, Tatsuki ^a   Imano, Motohiro ^c   Funakami, Yoshinori ^a   Ichida, Seiji ^a   Satou, Takao ^c   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b Sakai City Medical Center   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MEK; neuropathy; oxaliplatin; PKC

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OXALIPLATIN; PROTEIN C FOS; PROTEIN KINASE C; TAMOXIFEN; BENZAMIDE DERIVATIVE; DIPHENYLAMINE; PLATINUM COMPLEX; PROTEIN KINASE INHIBITOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; MALE; MOUSE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; HYPERALGESIA; PATHOLOGY; SIGNAL TRANSDUCTION; SPINAL CORD; TUMOR CELL LINE;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DIPHENYLAMINE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HYPERALGESIA; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; ORGANOPLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; SPINAL CORD; TAMOXIFEN;

EID: 84930416380     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29367     Document Type: Article

References (25)

1. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
2. Khattak MA,. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist 2011; 16: 1780-3.
3. Binder A, Stengel M, Maag R, et al. Pain in oxaliplatin-induced neuropathy-sensitisation in the peripheral and central nociceptive system. Eur J Cancer 2007; 43: 2658-63.
4. Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29: 21-33.
5. Pachman DR, Barton DL, Watson JC, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011; 90: 377-87.
6. Zhao M, Isami K, Nakamura S, et al. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 2012; 8: 55.
7. 2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain 2012; 8: 7.
8. Bautista DM, Jordt SE, Nikai T, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 2006; 124: 1269-82.
9. Munro FE, Fleetwood-Walker SM, Mitchell R,. Evidence for a role of protein kinase C in the sustained activation of rat dorsal horn neurons evoked by cutaneous mustard oil application. Neurosci Lett 1994; 170: 199-202.
10. Norcini M, Vivoli E, Galeotti N, et al. Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain 2009; 146: 141-7.
11. Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 2009; 30: 312-9.
12. Luo W, Sharif TR, Houghton PJ, et al. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Differ 1997; 8: 1225-40.
13. Matsuoka H, Tsubaki M, Yamazoe Y, et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res 2009; 315: 2022-32.
14. Lenfeld J, Kroutil M, Marsálek E, et al. Antiinflammatory activity of quaternary benzophenanthridine alkaloids from Chelidonium majus. Planta Med 1981; 43: 161-5.
15. Chmura SJ, Dolan ME, Cha A, et al. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res 2000; 6: 737-42.
16. Niu XF, Zhou P, Li WF, et al. Effects of chelerythrine, a specific inhibitor of cyclooxygenase-2, on acute inflammation in mice. Fitoterapia 2011; 82: 620-5.
17. Peng G, Han M, Du Y, et al. SIP30 is regulated by ERK in peripheral nerve injury-induced neuropathic pain. J Biol Chem 2009; 284: 30138-47.
18. Coggeshall RE,. Fos, nociception and the dorsal horn. Prog Neurobiol 2005; 77: 299-352.
19. Mandadi S, Roufogalis BD,. ThermoTRP channels in nociceptors: taking a lead from capsaicin receptor TRPV1. Curr Neuropharmacol 2008; 6: 21-38.
20. Fang YJ, Pan ZZ, Li LR, et al. MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cells. J Exp Clin Cancer Res 2009; 28: 132.
21. Detre S, Riddler S, Salter J, et al. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. Cancer Res 2003; 63: 6516-22.
22. Lien EA, Søiland H, Lundgren S, et al. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat 2013; 141: 243-8.
23. Ji RR, Gereau RW, 4th, Malcangio M, et al. MAP kinase and pain. Brain Res Rev 2009; 60: 135-48.
24. Imbe H, Okamoto K, Donishi T, et al. Activation of ERK in the locus coeruleus following acute noxious stimulation. Brain Res 2009; 1263: 50-7.
25. Leyton J, Smith G, Lees M, et al. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 2008; 7: 3112-21.